Napsagatran  (Synonyms: Ro 46-6240; Ro 46-6240/010)

Napsagatran (Ro 46-6240) is a potent thrombin inhibitor. Napsagatran exhibits anticoagulant effects in vitro and in vivo. Napsagatran can be used in antithrombotic research^[1][2].

Napsagatran (10 μg/kg/min) reduces platelet-rich thrombus formation in an ex vivo perfusion chamber model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Napsagatran (3-10 μg/kg/min) significantly prevents coronary artery occlusion and reduces intracoronary thrombus formation in a canine model of electrically induced arterial thrombosis^[1].
Napsagatran (10 μg/kg/min, i.v., infusion for 240 minutes) significantly reduces thrombus associated fibrin in rabbits^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

558.65

C₂₆H₃₄N₆O₆S

154397-77-0

O=C(NC[C@H]1CN(C(N)=N)CCC1)C[C@@H](C(N(C2CC2)CC(O)=O)=O)NS(C3=CC4=CC=CC=C4C=C3)(=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Roux S, et al. Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model. J Pharmacol Exp Ther. 1996 Apr;277(1):71-8.  [Content Brief]

  [2]. Himber J, et al. Inhibition of tissue factor limits the growth of venous thrombus in the rabbit. J Thromb Haemost. 2003 May;1(5):889-95.  [Content Brief]